Abstract

Synuclein-γ (SNCG) is overexpressed in many advanced stages cancers, including breast cancer, ovarian cancer, prostate cancer, lung cancer, liver cancer, esophagus cancer, and colon cancer.SNCG stimulates the proliferation, metastasis, and drug resistance of tumor cells, through interacting with BubR1 and damage mitotic checkpoint. A peptic ANK targeted at SNCG can inhibit activity of SNCG and may be developed as an adjuvant therapy. Key words: Synucleins; Neoplasms; Drug therapy

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.